Investors & Media

September 30, 2026

Immutep Receives ~A$0.86 Million R&D Tax Incentive

September 21, 2026

Change to American Depositary Share Ratio

September 11, 2026

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

July 30, 2026

Immutep Quarterly Activities Report Q4 FY26

July 24, 2026

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

July 14, 2026

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

August 20, 2026

Immutep Corporate Presentation

June 4, 2026

EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic

May 31, 2026

ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients

February 20, 2026

Immutep Corporate Presentation

December 2, 2025

SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003

November 13, 2025

CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)